Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Encorafenib, Cetuximab N01 and mFolfox6 for BRAF V600E Mutated/ pMMR Localized Colorectal Cancer With or Without Resectable Metastases: a Single Arm, Multi-center, Phase 2 Clinical Trial

NCT07789210 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT07789210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Encorafenib, Cetuximab N01 and mFolfox6 for BRAF V600E Mutated/ pMMR Localized Colorectal Cancer With or Without Resectable Metastases: a Single Arm, Multi-center, Phase 2 Clinical Trial
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2026
Completion date
June 30, 2031
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e mutation positive, cetuximab n01, colorectal cancer, encorafenib